SOPHiA GENETICS (NASDAQ:SOPH) CFO George Cardoza Sells 2,520 Shares

Key Points

• CFO George Cardoza sold 2,520 shares on April 6 at an average price of $4.85 under a Rule 10b5-1 plan to cover tax withholding, reducing his position by 0.85% to 295,274 shares (≈$1.43M).
• Cardoza also sold 2,413 shares on April 7 at $4.88 and 774 shares on March 19 at $4.79, reflecting additional sales tied to equity vesting and tax obligations.
• SOPH trades near $4.89 with a market cap of about $334.6M, negative EPS and margins, and a consensus "Hold" analyst view with a $7.00 target (two Buys, one Sell).

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) CFO George Cardoza sold 2,520 shares of the company's stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $4.85, for a total value of $12,222.00. Following the sale, the chief financial officer directly owned 295,274 shares of the company's stock, valued at $1,432,078.90. The trade was a 0.85% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

George Cardoza also recently made the following trade(s):

• On Tuesday, April 7th, George Cardoza sold 2,413 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.88, for a total value of $11,775.44.
• On Thursday, March 19th, George Cardoza sold 774 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.79, for a total value of $3,707.46.

SOPHiA GENETICS Stock Performance

SOPHiA GENETICS stock traded down $0.01 during trading hours on Wednesday, reaching $4.89. 64,929 shares of the company were exchanged, compared to its average volume of 188,371. The firm has a market cap of $334.64 million, a price-to-earnings ratio of -9.58 and a beta of 1.04. The company has a current ratio of 1.96, a quick ratio of 1.84 and a debt-to-equity ratio of 1.01. The stock has a 50-day moving average of $4.78 and a 200 day moving average of $4.68. SOPHiA GENETICS SA has a 12 month low of $2.58 and a 12 month high of $5.70.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last announced its earnings results on Tuesday, March 3rd. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.08). SOPHiA GENETICS had a negative return on equity of 50.60% and a negative net margin of 44.22%.The company had revenue of $21.71 million for the quarter, compared to the consensus estimate of $21.20 million. As a group, research analysts anticipate that SOPHiA GENETICS SA will post -0.96 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on SOPH shares. BTIG Research reiterated a "buy" rating and set a $7.00 price target on shares of SOPHiA GENETICS in a report on Tuesday, March 3rd. Guggenheim upped their price target on SOPHiA GENETICS from $6.00 to $7.00 and gave the stock a "buy" rating in a report on Monday, January 26th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of SOPHiA GENETICS in a report on Thursday, January 22nd. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $7.00.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. XTX Topco Ltd acquired a new position in shares of SOPHiA GENETICS during the fourth quarter worth approximately $55,000. Quadrature Capital Ltd bought a new stake in shares of SOPHiA GENETICS during the fourth quarter valued at approximately $54,000. Archon Capital Management LLC increased its position in shares of SOPHiA GENETICS by 3.4% during the fourth quarter. Archon Capital Management LLC now owns 441,413 shares of the company's stock valued at $2,061,000 after purchasing an additional 14,342 shares during the period. Renaissance Technologies LLC increased its position in shares of SOPHiA GENETICS by 169.5% during the fourth quarter. Renaissance Technologies LLC now owns 83,000 shares of the company's stock valued at $388,000 after purchasing an additional 52,200 shares during the period. Finally, Polen Capital Management LLC bought a new stake in shares of SOPHiA GENETICS during the fourth quarter valued at approximately $102,000. 31.59% of the stock is currently owned by institutional investors and hedge funds.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.